Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus PLENDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus PLENDIL.
CARDENE vs PLENDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
20-40 mg orally three times daily.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker